The watershed enactment of the 415-page Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) this past December provides pharmaceutical and biologics manufacturers with a series of new opportunities and challenges to provide prescription drugs to more than 40 million Medicare beneficiaries. Most of the popular press has rightfully focused on the cost of the drug benefit to seniors, with analysis aimed at premiums, co-payments, doughnut holes and first dollar coverage. Mor